Bronchial Asthma and diabetes mellitus: the challenge of cytokine regulation
DOI: 10.32364/2587-6821-2026-10-2-6
Bronchial Asthma and diabetes mellitus: the challenge of cytokine regulation
L.N. Sorokina, A.S. Pavlova, V.N. Mineev
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation
The combination of bronchial asthma (BA) and type 2 diabetes mellitus (T2DM) can currently be viewed from the perspective of comorbid pathology, in particular, pathology characterized by shared pathogenetic mechanisms. Available literature indicates that the association between BA and T2DM is bidirectional and independent. Specifically, patients with BA face an increased risk of developing T2DM, while patients with T2DM are conversely more likely to develop BA. Potential shared pathogenetic links for T2DM and BA include cytokine imbalance, oxidative stress, glycation, microangiopathy, and endothelial dysfunction. Subclinical inflammation, marked by an imbalance of pro- and anti-inflammatory cytokines, exerts both local and systemic effects, serving as a prerequisite for the development of various comorbid conditions. Glycation processes, and specifically the role of the receptor for advanced glycation end products (RAGE), are considered one of the pathophysiological mechanisms for complications not only within the context of T2DM pathogenesis but also as a foundation for the development of BA. Investigating the molecular basis of this pathogenesis is essential for the development of personalized diagnostic and therapeutic methods.
Keywords: bronchial asthma, diabetes mellitus, cytokines, glycation, inflammation, receptor for advanced glycation endproducts.
For citation: Sorokina L.N., Pavlova A.S., Mineev V.N. Bronchial Asthma and diabetes mellitus: the challenge of cytokine regulation. Russian Medical Inquiry. 2026;10(2):–106 (in Russ.). DOI: 10.32364/2587-6821-2026-10-2-6
About the authors:
Lada N. Sorokina — Dr. Sc. (Med.), Professor of the Department of Hospital Therapy named after Academician M.V. Chernorutsky with Clinic, Pavlov First Saint Petersburg State Medical University; 6-8, Lev Tolstoy str., St. Petersburg, 197022, Russian Federation; ORCID iD 0000-0001-6193-2774
Anastasia S. Pavlova — C. Sc. (Med.), Assistant Professor of the Department of Hospital Therapy named after Academician M.V. Chernorutsky with Clinic, Pavlov First Saint Petersburg State Medical University; 6-8, Lev Tolstoy str., St. Petersburg, 197022, Russian Federation; ORCID iD 0000-0001-7934-0718
Valeriy N. Mineev — Dr. Sc. (Med.), Professor of the Department of Hospital Therapy named after Academician M.V. Chernorutsky with Clinic, Pavlov First Saint Petersburg State Medical University; 6-8, Lev Tolstoy str., St. Petersburg, 197022, Russian Federation; ORCID iD 0000-0003-0352-8137
Contact information: Anastasia S. Pavlova, e-mail: heretofore@yandex.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 14.03.2026.
Revised 24.03.2026.
Accepted 27.03.2026.
2. Ненашева Н.М. Тезепелумаб — новый генно-инженерный биологический препарат для лечения тяжелой бронхиальной астмы. Практическая пульмонология. 2023;2:3–13. DOI: 10.24412/2409-6636-2023-12872Nenasheva N.M. Tezepelumab: a New Genetically Engineered Biological Drug for Treatment of Severe Asthma. Practical pulmonology. 2023;2:3–13 (in Russ.). DOI: 10.24412/2409-6636-2023-12872
3. Herder C., Carstensen M., Ouwens D.M. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab. 2013;15(Suppl 3):39–50. DOI: 10.1111/dom.12155
4. Драпкина О.М., Шутов А.М., Ефремова Е.В. Коморбидность, мультиморбидность, двойной диагноз — синонимы или разные понятия? Кардиоваскулярная терапия и профилактика. 2019;18(2):65–69. DOI: 10.15829/1728-8800-2019-2-65-69Drapkina O.M., Shutov A.M., Efremova E.V. Comorbidity, multimorbidity, dual diagnosis — synonyms or different terms? Cardiovascular Therapy and Prevention. 2019;18(2):65–69 (in Russ.). DOI: 10.15829/1728-8800-2019-2-65-69
5. Tomisa G., Horváth A., Sánta B. et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol. 2021;17(1):95. DOI: 10.1186/s13223-021-00598-3
6. Rayner L., McGovern A., Creagh-Brown B. et al. Type 2 Diabetes and Asthma: Systematic Review of the Bidirectional Relationship. Curr Diabetes Rev. 2019;15(2):118–126. DOI: 10.2174/1573399814666180711114859
7. Zheng H., Wu J., Jin Z. et al. Potential Biochemical Mechanisms of Lung Injury in Diabetes. Aging Dis. 2017;8(1):7–16. DOI: 10.14336/AD.2016.0627
8. Pitocco D., Fuso L., Conte E.G. et al. The diabetic lung-a new target organ? Rev Diabet Stud. 2012;9(1):23–35. DOI: 10.1900/RDS.2012.9.23
9. Kolahian S., Leiss V., Nürnberg B. Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord. 2019;20(3):303–319. DOI: 10.1007/s11154-019-09516-w
10. Hsia C.C., Raskin Р. Lung involvement in diabetes: does it matter? Diabetes Care. 2008;4(31):828–829. DOI: 10.2337/dc08-0103
11. Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546–3556. DOI: 10.1172/JCI36130
12. Habib N., Pasha M.A., Tang D.D. Current Understanding of Asthma Pathogenesis and Biomarkers. Cells. 2022;11(17):2764. DOI: 10.3390/cells11172764
13. Asadikaram G., Ram M., Izadi A. et al. The study of the serum level of IL-4, TGF-β, IFN-γ, and IL-6 in overweight patients with and without diabetes mellitus and hypertension. J Cell Biochem. 2019;120(3):4147–4157. DOI: 10.1002/jcb.27700
14. Spranger J., Kroke A., Möhlig M. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812–817. DOI: 10.2337/diabetes.52.3.812
15. Williams A., Greene N., Kimbro K. Increased circulating cytokine levels in African American women with obesity and elevated HbA1c. Cytokine. 2020;128:154989. DOI: 10.1016/j.cyto.2020.154989
16. Cao Y., Li Y., Han W. et al. Sodium Butyrate Ameliorates Type 2 Diabetes-Related Sarcopenia Through IL-33-Independent ILC2s/IL-13/STAT3 Signaling Pathway. J Inflamm Res. 2023;16:343–358. DOI: 10.2147/JIR.S392350
17. Andrews A.L., Holloway J.W., Holgate S.T. et al. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol. 2006;176(12):7456–7461. DOI: 10.4049/jimmunol.176.12.7456
18. Kankaanranta H., Kauppi P., Tuomisto L.E. et al. Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms. Mediators Inflamm. 2016;2016:3690628. DOI: 10.1155/2016/3690628
19. Rincon M., Irvin C.G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8(9):1281–1290. DOI: 10.7150/ijbs.4874
20. Иванов В., Рубеко Е., Сорокина Л. и др. Бронхиальная астма в сочетании с сахарным диабетом типа 2: клинико-патогенетические особенности. Врач. 2016;7:36–38.Ivanov V., Rubeko E., Sorokina L. et al. Bronchial asthma concurrent with type 2 diabetes mellitus: clinical and pathogenetic features. Vrach. 2016;7:36–38 (in Russ.).
21. O'Connor J.C., Sherry C.L., Guest C.B. еt al. Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3. J Immunol. 2007;178(11):6886–6893. DOI: 10.4049/jimmunol.178.11.6886
22. Adela R., Banerjee S. Role of inflammatory mediators in diabetes and cardiovascular diseases. International Journal of Technology Management. 2015;4(1):62–70.
23. Стафеев Ю.С., Мичурина С.С., Подкуйченко Н.В. и др. Интерлейкин-4 восстанавливает чувствительность к инсулину в адипоцитарной модели липид-индуцированной инсулиновой резистентности. Биохимия. 2018;83(5):662–672.Stafeev I.S., Michurina S.S., Podkuychenko N.V. Interleukin-4 restores insulin sensitivity in lipid-induced insulin resistant adipocytes. Biochemistry. 2018;83(5):662–672 (in Russ.).
24. Marini M., Vittori E., Hollemborg J. et al. Expression of the potent inflammatory cytokines, granulocytemacrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. J Allergy Clin Immunol. 1992;89(5):1001–1009. DOI: 10.1016/0091-6749(92)90223-o
25. Neveu W.A., Allard J.L., Raymond. D.M. et al. Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Resp Res. 2010;11(1):28. DOI: 10.1186/1465-9921-11-28
26. Chen H., Ren X., Liao N. et al. Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy. J Int Med Res. 2016;6(44):1403–1413. DOI: 10.1177/0300060516672369
27. Hughes M.J., McGettrick H.M., Sapey E. Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2 diabetes: the neutrophil as a potential inflammatory target. Eur Respir Rev. 2020;29(155):190102. DOI: 10.1183/16000617.0102-2019
28. Galicia-Garcia U., Benito-Vicente A., Jebari S. et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(17):6275. DOI: 10.3390/ijms21176275
29. Akash M.S.H., Rehman K., Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J Cell Biochem. 2018;119(1):105–110. DOI: 10.1002/jcb.26174
30. Kraik K., Tota M., Laska J. et al. The Role of Transforming Growth Factor-β (TGF-β) in Asthma and Chronic Obstructive Pulmonary Disease (COPD). Cells. 2024;13(15):1271. DOI: 10.3390/cells13151271
31. Tuleta I., Frangogiannis N.G. Diabetic fibrosis. Biochim Biophys Acta Mol Basis Dis. 2021;1867(4):166044. DOI: 10.1016/j.bbadis.2020.166044
32. Гаврилова А.О., Северина А.С., Шамхалова М.Ш. и др. Роль конечных продуктов гликирования в патогенезе диабетической нефропатии. Сахарный диабет. 2021;24(5):461–469. DOI: 10.14341/DM12784Gavrilova A.O., Severina A.S., Shamhalova M.S. et al. The role of advanced glycation end products in patogenesis of diabetic nephropathy. Diabetes mellitus. 2021;24(5):461–469 (in Russ.). DOI: 10.14341/DM12784
33. Dennis R.J., Maldonado D., Rojas M.X. et al. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: A cross-sectional study. BMC Pulm Med. 2010;10:38. DOI: 10.1186/1471-2466-10-38
34. Oczypok E.A., Perkins T.N., Oury T.D. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev. 2017;23:40–49. DOI: 10.1016/j.prrv.2017.03.012
35. Milutinovic P.S., Alcorn J.F., Englert J.M. et al. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am J Pathol. 2012;181(4):1215–1225. DOI: 10.1016/j.ajpath.2012.06.031
36. Zhang F., Su X., Huang G. et al. sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells. Sci Rep. 2017;7(1):14268. DOI: 10.1038/s41598-017-14667-4
37. Chen Y., Akirav E.M., Chen W. et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008;181(6):4272–4278. DOI: 10.4049/jimmunol.181.6.4272
38. Сорокина Л.Н., Павлова А.С., Минеев В.Н. и др. Растворимый рецептор к конечным продуктам гликирования у больных бронхиальной астмой. Пульмонология. 2025;35(6):776–783. DOI: 10.18093/0869-0189-2025-35-6-776-783Sorokina L.N., Pavlova A.S., Mineev V.N. et al. Soluble receptor for advanced glycation end products in patients with asthma. Pulmonologiya. 2025;35(6):776–783 (in Russ.). DOI: 10.18093/0869-0189-2025-35-6-776-783
39. Uz-Zaman S., Banerjee J., Singhamahapatra A. et al. Assessment of lung function by spirometry and diffusion study and effect of glycemic control on pulmonary function in type 2 diabetes mellitus patients of the Eastern India. J Clin Diagn Res. 2014;8(11):BC01–04. DOI: 10.7860/JCDR/2014/ 9756.5076
40. Иванов В.А., Сорокина Л.Н., Минеев В.Н. и др. Сочетание бронхиальной астмы и сахарного диабета: синергизм или антагонизм? Пульмонология. 2014;(6):103–107. DOI: 10.18093/0869-0189-2014-0-6-103-107Ivanov V.A., Sorokina L.N., Mineev V.N. et al. Comorbidity of asthma and diabetes: synergism or antagonism? Pulmonologiya. 2014;(6):103–107 (in Russ.). DOI: 10.18093/0869-0189-2014-0-6-103-107
41. Aparna. Pulmonary function tests in type 2 diabetics and non-diabetic people -a comparative study. J Clin Diagn Res. 2013;7(8):1606–1608. DOI: 10.7860/JCDR/2013/6182.3237
42. Минеев В.Н., Сорокина Л.Н., Павлова А.С. Диабетическая болезнь легких как дискуссионная проблема. Практическая пульмонология. 2024;(2):46–50. DOI: 10.24412/2409-6636-2024-13148Mineev V.N., Sorokina L.N., Pavlova A.S. Diabetic Lung Disease as a Discussion Problem. Practical pulmonology. 2024;(2):46–50 (in Russ.). DOI: 10.24412/2409-6636-2024-13148
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать